stockrow
Friday 6 November 2026
Export PCVX’s income statement to Excel — free account
Vaxcyte, Inc.
PCVX Healthcare Biotechnology
- EPS
- −61.5%
- Free cash flow
- −92.6%
Quarter to June 2026, against a year earlier
63.94
2.02
+3.26%
Follow PCVX
Alert me
Vaxcyte, Inc. (PCVX) EPS (diluted)
Vaxcyte, Inc.'s EPS (diluted) for fiscal 2025 was −$5.63, compared with −$3.80 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$7.63. Over the past ten years it has ranged from −$13.25 (fiscal 2019) to −$1.93 (fiscal 2021); the current reading is higher than 38% of that period. Vaxcyte, Inc. ranks 478th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$5.63 | — |
| FY2024 | −$3.80 | — |
| FY2023 | −$4.14 | — |
| FY2022 | −$3.44 | — |
| FY2021 | −$1.93 | — |
| FY2020 | −$3.02 | — |
| FY2019 | −$13.25 | — |
| FY2018 | −$8.12 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.97 | — |
| Mar 2026 | −$2.30 | — |
| Dec 2025 | −$1.80 | — |
| Sep 2025 | −$1.56 | — |
| 24 more quarters | Free account |
Against its own ten years
Low −$13.25
High −$1.93
Ten-year median
−$3.97
Current reading's percentile
38
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| TGTX TG Therapeutics, Inc. compare | $2.74 |
| TECH Bio-Techne Corp compare | $1.15 |
| PTGX Protagonist Therapeutics, Inc. compare | $1.03 |
| CAI Caris Life Sciences,�Inc. compare | $0.33 |
| BMRN BioMarin Pharmaceutical Inc. compare | −$0.10 |
| IBRX ImmunityBio, Inc. compare | −$0.97 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$5.98 |
| PCVX Vaxcyte, Inc. | −$7.63 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item